Rapid Dose Therapeutics Corp. (DOSE.CN)
CAD 0.2
(0.0%)
CAD 0.2
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.73 Million CAD | 12.99% |
| 2022 | -3.54 Million CAD | 17.62% |
| 2021 | -4.3 Million CAD | -102.25% |
| 2020 | -2.12 Million CAD | 71.66% |
| 2019 | -7.5 Million CAD | -129.15% |
| 2018 | -3.27 Million CAD | -6440.25% |
| 2017 | -50.07 Thousand CAD | -6.33% |
| 2016 | -47.09 Thousand CAD | 8.98% |
| 2015 | -51.74 Thousand CAD | -169.47% |
| 2014 | -19.2 Thousand CAD | 33.89% |
| 2013 | -29.04 Thousand CAD | 62.05% |
| 2012 | -76.53 Thousand CAD | -13.02% |
| 2011 | -67.72 Thousand CAD | 15.3% |
| 2010 | -79.95 Thousand CAD | -1074.96% |
| 2009 | -6805.00 CAD | -101.39% |
| 2008 | -3379.00 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -857.51 Thousand CAD | 10.14% |
| 2024 Q1 | -954.25 Thousand CAD | 17.8% |
| 2023 Q3 | -878.49 Thousand CAD | -57.89% |
| 2023 FY | -3.08 Million CAD | 12.99% |
| 2023 Q1 | -465.16 Thousand CAD | 59.92% |
| 2023 Q2 | -556.4 Thousand CAD | -19.61% |
| 2023 Q4 | -1.16 Million CAD | -32.15% |
| 2022 Q4 | -1.16 Million CAD | -118.32% |
| 2022 Q1 | -977.7 Thousand CAD | 54.74% |
| 2022 Q2 | -873.77 Thousand CAD | 10.63% |
| 2022 FY | -3.54 Million CAD | 17.62% |
| 2022 Q3 | -531.65 Thousand CAD | 39.15% |
| 2021 FY | -4.3 Million CAD | -102.25% |
| 2021 Q1 | -766.4 Thousand CAD | 6.28% |
| 2021 Q2 | -694.49 Thousand CAD | 9.38% |
| 2021 Q3 | -787.07 Thousand CAD | -13.33% |
| 2021 Q4 | -2.16 Million CAD | -174.44% |
| 2020 FY | -2.12 Million CAD | 71.66% |
| 2020 Q2 | -462.42 Thousand CAD | 1.28% |
| 2020 Q3 | -521.03 Thousand CAD | -12.68% |
| 2020 Q4 | -817.75 Thousand CAD | -56.95% |
| 2020 Q1 | -468.4 Thousand CAD | 48.86% |
| 2019 FY | -7.5 Million CAD | -129.15% |
| 2019 Q4 | -915.92 Thousand CAD | 67.19% |
| 2019 Q1 | -3.17 Million CAD | 67.15% |
| 2019 Q3 | -2.79 Million CAD | -283.33% |
| 2019 Q2 | -728.29 Thousand CAD | 77.08% |
| 2018 Q2 | -504.32 Thousand CAD | -68.94% |
| 2018 Q1 | -298.51 Thousand CAD | 75.61% |
| 2018 FY | -3.27 Million CAD | -6440.25% |
| 2018 Q3 | -1 Million CAD | -99.46% |
| 2018 Q4 | -9.67 Million CAD | -861.6% |
| 2017 Q2 | -26.76 Thousand CAD | -319.2% |
| 2017 Q1 | -6384.00 CAD | -61.87% |
| 2017 Q4 | -1.22 Million CAD | -6215.03% |
| 2017 Q3 | -19.37 Thousand CAD | 27.59% |
| 2017 FY | -50.07 Thousand CAD | -6.33% |
| 2016 Q2 | -16.47 Thousand CAD | -823.14% |
| 2016 FY | -47.09 Thousand CAD | 8.98% |
| 2016 Q3 | -12.98 Thousand CAD | 21.17% |
| 2016 Q4 | -3944.00 CAD | 69.64% |
| 2016 Q1 | -1785.00 CAD | 89.47% |
| 2015 Q2 | -14.57 Thousand CAD | -69.02% |
| 2015 Q4 | -16.94 Thousand CAD | -42.69% |
| 2015 FY | -51.74 Thousand CAD | -169.47% |
| 2015 Q3 | -11.87 Thousand CAD | 18.48% |
| 2015 Q1 | -8621.00 CAD | -9.28% |
| 2014 Q4 | -7889.00 CAD | 61.82% |
| 2014 Q1 | -33.46 Thousand CAD | -308.33% |
| 2014 FY | -19.2 Thousand CAD | 33.89% |
| 2014 Q3 | -20.66 Thousand CAD | -175.51% |
| 2014 Q2 | 27.36 Thousand CAD | 181.78% |
| 2013 FY | -29.04 Thousand CAD | 62.05% |
| 2013 Q4 | -8195.00 CAD | -61.16% |
| 2013 Q3 | -5085.00 CAD | 63.02% |
| 2013 Q2 | -13.75 Thousand CAD | -446.98% |
| 2013 Q1 | -2514.00 CAD | 74.14% |
| 2012 Q1 | -32.98 Thousand CAD | -94.83% |
| 2012 Q4 | -9723.00 CAD | -217.85% |
| 2012 Q2 | -21.51 Thousand CAD | 34.76% |
| 2012 FY | -76.53 Thousand CAD | -13.02% |
| 2012 Q3 | -3059.00 CAD | 85.78% |
| 2011 Q2 | -36.89 Thousand CAD | -386.65% |
| 2011 Q3 | -5105.00 CAD | 86.16% |
| 2011 Q4 | -16.92 Thousand CAD | -231.62% |
| 2011 FY | -67.72 Thousand CAD | 15.3% |
| 2011 Q1 | -7582.00 CAD | 38.6% |
| 2010 Q2 | -14.15 Thousand CAD | -100.82% |
| 2010 Q1 | -7050.00 CAD | 86.91% |
| 2010 FY | -79.95 Thousand CAD | -1074.96% |
| 2010 Q4 | -12.34 Thousand CAD | -13.39% |
| 2010 Q3 | -10.89 Thousand CAD | 23.08% |
| 2009 Q3 | -4886.00 CAD | -142.0% |
| 2009 FY | -6805.00 CAD | -101.39% |
| 2009 Q1 | -1225.00 CAD | 40.1% |
| 2009 Q4 | -53.86 Thousand CAD | -1002.37% |
| 2009 Q2 | -2019.00 CAD | -64.82% |
| 2008 Q3 | -4516.00 CAD | 0.0% |
| 2008 Q4 | -2045.00 CAD | 54.72% |
| 2008 FY | -3379.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -5.01 Million CAD | 25.493% |
| Asep Medical Holdings Inc | -7.72 Million CAD | 51.578% |
| BetterLife Pharma Inc. | -3.24 Million CAD | -15.386% |
| BioVaxys Technology Corp. | -2.4 Million CAD | -55.614% |
| ChitogenX Inc. | -2.83 Million CAD | -32.112% |
| Defence Therapeutics Inc. | -12.65 Million CAD | 70.458% |
| Entheon Biomedical Corp. | -313.99 Thousand CAD | -1090.725% |
| Gemina Laboratories Ltd. | -5.08 Million CAD | 26.487% |
| Glow Lifetech Corp. | -1.64 Million CAD | -127.598% |
| Lexston Life Sciences Corp. | -674.71 Thousand CAD | -454.125% |
| Pharmala Biotech Holdings Inc. | -762.95 Thousand CAD | -390.043% |
| Doseology Sciences Inc. | -377.63 Thousand CAD | -890.057% |
| MYND Life Sciences Inc. | -1.8 Million CAD | -106.816% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | -210.969% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | -22.821% |
| PreveCeutical Medical Inc. | -963.12 Thousand CAD | -288.193% |
| Telescope Innovations Corp. | -5.76 Million CAD | 35.167% |